NR3C2 and malignant colon neoplasm: To confirm PKC and EGFR activation play a role in MR agonist-induced binding of βPix to β-catenin, we treated HT-29 colon cancer cells with phorbol 12-myristate, 13-acetate (PMA), a selective PKC activator and epidermal growth factor (EGF).